Real-World Treatment Patterns & Characteristics of Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of US Claims (2017-2024)

被引：0
|
作者：
Burke, John M. [1 ,2 ]
Zhou, Ziqi [3 ]
Gutierrez, Cynthia [3 ]
Shao, Anran [4 ]
Boyd, Marley [4 ]
Noshad, Sina [3 ]
Hohlbauch, Andriana [3 ]
Liu, Nicholas [5 ]
Repetny, Karen [5 ]
Fanale, Michelle [5 ]
Mitchell, Betsy [5 ]
Phillips, Tycel [6 ]
机构：
[1] Sarah Cannon Res Inst, Aurora, CO USA
[2] Rocky Mt Canc Ctr, Aurora, CO USA
[3] Genesis, Hoboken, NJ USA
[4] Genesis Res Grp, Hoboken, NJ USA
[5] Pfizer, New York, NY USA
[6] City Of Hope, Dept Hematol & Oncol, Duarte, CA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203554
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7810 / 7811
页数：2
相关论文
共 50 条
  • [31] Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma
    Chien, Hsu-Chih
    Morreall, Deborah
    Patil, Vikas
    Rasmussen, Kelli M.
    Li, Chungyang
    Yong, Christina M.
    Burningham, Zachary
    Masaquel, Anthony
    Halloran, Mary
    De Long-Sieg, Elisha
    Schulz, Mathias
    Sauer, Brian C.
    Halwani, Ahmad S.
    FUTURE ONCOLOGY, 2020, 17 (04) : 411 - 422
  • [32] Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma
    Wang, Xiaoyan
    Yu, Lu
    Jiang, Xinlu
    Ding, Kaiyang
    CANCER MEDICINE, 2023, 12 (09): : 10553 - 10562
  • [33] Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database.
    Burke, John M.
    Wang, Rongrong
    Hossain, Farah
    Li, Jia
    Masaquel, Anthony
    Matasar, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: A real-world analysis.
    Xu, Peng-Peng
    Liu, Tingbo
    Li, Zengjun
    Li, Zheng
    Huang, Wei
    Zhou, Keshu
    Cai, Mingci
    Shen, Rong
    Zhao, Weili
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) - a Retrospective Health Claims Data Analysis
    Borchmann, Peter
    Papadimitrious, Michael S.
    Mahlich, Joerg
    Riou, Sybille
    Werner, Barbara
    BLOOD, 2022, 140 : 7932 - 7932
  • [36] Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma
    Tsutsue, Saaya
    Tobinai, Kensei
    Yi, Jingbo
    Crawford, Bruce
    PLOS ONE, 2020, 15 (08):
  • [37] Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
    Saverno, Kimberly
    Nastoupil, Loretta
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Gentile, Danielle
    Asgarisabet, Parisa
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2375 - 2376
  • [38] Outcomes of Patients with Transformed Diffuse Large B-Cell Lymphoma (DLBCL)
    Nakashima, J.
    Cruz-Chamarro, R.
    Laborde, J.
    Kim, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E479 - E479
  • [39] Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
    Borchmann, Peter
    Papadimitrious, Michael
    Riou, Sybille
    Mahlich, Joerg
    Werner, Barbara
    BLOOD, 2022, 140 : 7919 - 7919
  • [40] Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database
    Borchmann, Peter
    Heger, Jan-Michel
    Mahlich, Joerg
    Papadimitrious, Michael S.
    Riou, Sybille
    Werner, Barbara
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7091 - 7101
12345